Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. - Bahlis NJ; Zonder J; Karlin L; Plesner T; Paris L; Wrobel T; Hungria V; Besemer B; Crusoe E; Silkjaer T; Perrot A; Moreau P; et al. (Leukemia & lymphoma, 2025)